Latest news with #ETH47
Yahoo
26-06-2025
- Business
- Yahoo
Thermo Fisher, Ethris Partner to Offer Integrated mRNA Solutions for Biopharma
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims to provide a fully integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers globally. The core objective of the collaboration is to accelerate the progression of candidate mRNA medicines from the research phase to clinical proof-of-concept. The partnership will use Ethris' advanced mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM RNA), minimal UTR, and mRNA manufacturing technologies. These will be combined with Thermo Fisher Scientific's industry-leading end-to-end good manufacturing practice/GMP-compliant manufacturing capabilities. A workstation in a research lab stocked with laboratory products and services. Ethris' platform technologies have already shown promising results. Specifically, the company's lead candidate, ETH47, has shown favorable outcomes in Phase I trials. ETH47 is designed for local administration via nasal spray to target asthma exacerbations and showed dose-dependent and localized production of the encoded protein (interferon lambda) at the site of administration, with no systemic bioavailability. The study confirmed the functional activity of the expressed protein by activating downstream signaling. The non-immunogenic nature of SNIM RNAs allows for repeated administration, which leads to sustained production of therapeutically active proteins within the human body. The technology is versatile, suitable for multiple routes of administration, and can be used to replace or augment missing or non-functional proteins, introduce new proteins to modulate disease, or develop vaccines. Thermo Fisher Scientific Inc. (NYSE:TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services internationally. Ethris is a clinical-stage biotechnology company that has paved a new path from genes to therapeutic proteins. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-06-2025
- Business
- Yahoo
Thermo Fisher, Ethris Partner to Offer Integrated mRNA Solutions for Biopharma
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims to provide a fully integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers globally. The core objective of the collaboration is to accelerate the progression of candidate mRNA medicines from the research phase to clinical proof-of-concept. The partnership will use Ethris' advanced mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM RNA), minimal UTR, and mRNA manufacturing technologies. These will be combined with Thermo Fisher Scientific's industry-leading end-to-end good manufacturing practice/GMP-compliant manufacturing capabilities. A workstation in a research lab stocked with laboratory products and services. Ethris' platform technologies have already shown promising results. Specifically, the company's lead candidate, ETH47, has shown favorable outcomes in Phase I trials. ETH47 is designed for local administration via nasal spray to target asthma exacerbations and showed dose-dependent and localized production of the encoded protein (interferon lambda) at the site of administration, with no systemic bioavailability. The study confirmed the functional activity of the expressed protein by activating downstream signaling. The non-immunogenic nature of SNIM RNAs allows for repeated administration, which leads to sustained production of therapeutically active proteins within the human body. The technology is versatile, suitable for multiple routes of administration, and can be used to replace or augment missing or non-functional proteins, introduce new proteins to modulate disease, or develop vaccines. Thermo Fisher Scientific Inc. (NYSE:TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services internationally. Ethris is a clinical-stage biotechnology company that has paved a new path from genes to therapeutic proteins. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
16-06-2025
- Business
- Yahoo
Ethris and Thermo Fisher partner on mRNA solutions
Ethris has entered a strategic partnership with Thermo Fisher Scientific to provide a completely integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers. The partnership aims to accelerate the progression of candidate mRNA medicines from research to clinical proof-of-concept. It will combine Ethris' advanced technology platforms with Thermo Fisher's good manufacturing practice-compliant manufacturing capabilities. Ethris CEO Carsten Rudolph stated: 'Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies. 'By combining our clinically validated mRNA platforms with Thermo Fisher's manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scaleable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.' The collaboration will expand worldwide access to Ethris' suite of mRNA technologies, including its stabilised non-immunogenic mRNA (SNIM RNA). SNIM RNAs are non-immunogenic and can therefore be administered repeatedly, resulting in sustained production of proteins that are therapeutically active within the human body. These platforms are designed for safe drug production while allowing scaleable manufacturing processes. Ethris' platform technologies have shown favourable results in Phase I trials for ETH47, a candidate targeting asthma exacerbations through nasal administration. The trial data indicated dose-dependent protein production at the site without systemic bioavailability. Thermo Fisher scientific large molecule drug substance vice-president and general manager Ben Castro stated: 'Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application. 'By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.' "Ethris and Thermo Fisher partner on mRNA solutions" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Business Wire
13-06-2025
- Business
- Business Wire
Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms
MUNICH--(BUSINESS WIRE)-- Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers. The collaboration brings together Ethris' comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM ® RNA), minimal UTR and mRNA manufacturing technologies with Thermo Fisher's industry-leading end-to-end GMP-compliant manufacturing capabilities. Broadening global access to Ethris' comprehensive suite of mRNA technology platforms, the partners will facilitate the ability of biopharmaceutical developers to rapidly advance candidate mRNA medicines from research to clinical proof-of-concept. 'Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies,' said Dr. Carsten Rudolph, CEO of Ethris. 'By combining our clinically validated mRNA platforms with Thermo Fisher's manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scalable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.' The collaboration will also support the continued optimization of Ethris' platform technologies, which have already demonstrated positive pharmacodynamic effects, safety and targeted engagement in Phase 1 topline data of its lead candidate, ETH47. Designed for local administration via nasal spray to address the upstream trigger of asthma exacerbations, ETH47 showed dose-dependent, localized production of the encoded protein, interferon lambda at the site of administration, with no systemic bioavailability. The study confirmed that ETH47 activated downstream signaling, demonstrating the expressed protein's functional activity. Given its non-immunogenic nature, SNIM® RNAs can be administered repeatedly, leading to sustained production of therapeutically active proteins within the human body. Eligible for multiple routes of administration, the technology can replace or augment missing or non-functional proteins that cause a disease, introduce new proteins to modulate the course of the disease or its symptoms and be used to develop vaccines. 'Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application,' said Ben Castro, Vice President and General Manager, Large Molecule, Drug Substance, Thermo Fisher Scientific. 'By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.' Ethris' SNIM® RNA platform sets new standards for mRNA therapeutics by enabling safe, efficacious and stable drug products as well as scalable manufacturing, expanding the potential of mRNA medicines. About Ethris Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. For more information, visit
Business Wire
06-05-2025
- Health
- Business Wire
Ethris Receives €10 Million EU4Health Grant to Support Clinical Development and Expand Antiviral Applications of Lead mRNA Candidate ETH47
MUNICH--(BUSINESS WIRE)-- Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it was awarded a €10 million grant from EU4Health, the EU's largest health programme committed to a healthier European Union. The funding will support NoVir, a comprehensive project including several preclinical and clinical studies to evaluate the potential of ETH47, Ethris' lead, first-in-class mRNA-based antiviral therapy. Designed as a broad-spectrum antiviral with a virus- and mutation-independent mechanism of action, ETH47 offers a promising approach for pandemic preparedness. 'The EU4Health grant is a significant validation of ETH47's pioneering approach and its potential to offer a paradigm shift in the treatment and prevention of respiratory and broader systemic infections,' said Dr. Carsten Rudolph, CEO of Ethris. 'ETH47's ability to act at virus entry sites, combined with its room-temperature stability and potential synergy with existing antivirals, positions it as a differentiated and scalable solution for pandemic preparedness. The funding enables us to advance ETH47's clinical development and explore its wider applications beyond respiratory conditions, to address additional critical unmet needs in high-risk populations.' The NoVir study will run from May 1, 2025, to April 31, 2027 and will include the following projects: A clinical rhinovirus challenge study in asthmatic and chronic obstructive pulmonary disease (COPD) patients, populations at high risk for severe viral infections. A clinical study in healthy volunteers infected with influenza to assess ETH47's antiviral efficacy. Preclinical research exploring ETH47's protective effects against paramyxoviruses, orthomyxoviruses, coronaviridae, and bunyaviruses, including those responsible for viral hemorrhagic fevers (VHFs). Investigation into ETH47's impact on intravaginal, ocular, and systemic infections, through multiple routes of administration, expanding its potential use beyond respiratory illnesses. Evaluation of ETH47's ability to enhance the efficacy of existing antiviral treatments through synergistic effects. NoVir includes collaborations with the Technical University of Munich (TUM) and Aarhus University for the preclinical research of ETH47's protective effect against different virus classes and via different infection routes. The universities' research is driven by their leading virology laboratories, which empower the project with expertise in virus systems and their replication, as well as with their established cell and animal models. The EU4Health programme was established in response to the COVID-19 pandemic and is a European Union initiative aimed at strengthening Europe's healthcare systems and improving preparedness for future health crises. With a budget of €4.4 billion, it focuses on enhancing health promotion, disease prevention, crisis response, and healthcare access. The programme supports projects addressing long-term health challenges and contributes to the creation of a healthier European Union. About ETH47 ETH47 is Ethris' first-in-class mRNA-based product candidate encoding interferon lambda (IFNλ) that was developed using the company's Stabilized Non-Immunogenic mRNA (SNIM ® RNA) platform, and uniquely designed to be administered locally to the respiratory tract through inhalation or nasal spray using Ethris' proprietary Stabilized NanoParticle (SNaP ®) LNP platform. ETH47 is meant to induce a mucosal innate immune defense response at virus entry sites as well as inhibit viral replication. ETH47's versatile, virus- and mutation-independent mode of action has the potential to broadly address seasonal and emerging respiratory virus infections, including virus-driven exacerbation of chronic respiratory diseases such as asthma. About Ethris Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives.
